Physician profile
Christopher M Roberson
NPI 1629650189
$1,834.07
in general payments reported to CMS, 2019-2025
24 companies · $776 in 2025
The $776 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $73.23 · 2023: $16.15 · 2024: $476 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.24 | 2021-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $387.05 | 2025 | Sunlenca |
| Novo Nordisk INC | $254.13 | 2021-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $114.68 | 2024-2025 | Xyosted |
| Indivior INC. | $56.38 | 2021-2025 | Sublocade |
| Abbvie INC. | $55.97 | 2021 | |
| Amgen INC. | $55.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.00 | 2021 | |
| Merck Sharp & Dohme LLC | $39.41 | 2021 | |
| Eisai INC. | $38.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.07 | 2021-2022 | |
| Pfizer INC. | $31.08 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $29.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.70 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.72 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $23.68 | 2021 | |
| Biogen, INC. | $23.43 | 2021 | |
| Phadia US INC. | $20.06 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2022 | |
| Ibsa Pharma INC. | $15.44 | 2021 | |
| Qol Medical, LLC | $12.87 | 2021 | |
| Grifols USA, LLC | $12.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.75 | 2022 | |
| Lilly USA, LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.